Abbott Laboratories Stock (ABT) Moved Down by 3.04% on Apr 10: A Full Analysis

Abbott Laboratories (ABT) experienced a notable decline today, driven primarily by a significant legal setback and concurrent negative market sentiment. A jury in Chicago has ordered Abbott to pay $53 million in compensatory damages to families in a lawsuit alleging that the company's premature infant formula caused necrotizing enterocolitis (NEC). This verdict has heightened concerns regarding potential litigation risks and could lead to further financial liabilities as the jury is yet to deliberate on punitive damages.

The stock also reached a 52-week low today, underscoring a challenging period for the company and reflecting a substantial year-long decline. This technical milestone can intensify selling pressure as it signals a breach of historical support levels. Adding to the negative momentum, Goldman Sachs recently lowered its price target for ABT to $121.00 from $140.00, despite maintaining a 'Buy' rating. Other analysts also adjusted their price targets downwards earlier in the month, contributing to a cautious outlook from the investment community.

Investors are also looking ahead to Abbott's upcoming first-quarter 2026 earnings release, scheduled for April 16, 2026. The proximity of this announcement, coupled with the projected dilution of Abbott's 2026 adjusted earnings per share by approximately $0.20 due to its recent acquisition of Exact Sciences, is likely fostering increased investor uncertainty and volatility. While the company has declared a quarterly dividend, this positive financial event appears to be overshadowed by the more immediate and impactful negative news.

Technically, Abbott Laboratories (ABT) shows a MACD (12,26,9) value of [-2.44], indicating a neutral signal. The RSI at 37.18 suggests neutral condition and the Williams %R at -73.32 suggests oversold condition. Please monitor closely.

Abbott Laboratories (ABT) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.33B, ranking 3 in the industry. The net profit is $6.52B, ranking 2 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $132.05, a high of $158.00, and a low of $113.00.

Company Specific Risks:

• Abbott faces significant legal and financial exposure following a Cook County jury ordering the company to pay at least $53 million in compensatory damages for its premature infant formula causing necrotizing enterocolitis (NEC), with punitive damages still pending and over 1,700 similar lawsuits nationwide.
• The Nutrition segment continues to exhibit weakness, highlighted by a 9.1% organic sales decline in Q4 2025, primarily due to market-share losses in the U.S. pediatric business and adverse pricing dynamics.
• Multiple institutional analysts have recently reduced their price targets for ABT, signaling cautious sentiment regarding future growth prospects and reflecting concerns over revenue shortfalls and a challenging outlook.
• The Diagnostics segment faces ongoing headwinds from Volume-Based Procurement (VBP) programs in China, which are placing pressure on pricing and volume, contributing to flat organic growth in the base business (excluding COVID testing).